[ad_1]
New data suggests that people whose immune systems have responded strongly to the MMR vaccine may be less likely to be severely infected with the emerging coronavirus. The MMR2 vaccine, manufactured by Merck and licensed in 1979, stimulates the immune system to produce antibodies.
On Friday (November 20, 2020), researchers reported in the journal Mbio that it was found that among the 50 Covid-19 patients under the age of 42 who had been vaccinated with the MMR2 vaccine as children, the highest levels of The antibody called EGJ produced by the vaccine and directed against the mumps virus in particular, if its symptoms are less severe.
And Covid-19 was asymptomatic in people who had the highest level of antibodies to mumps.
More research is needed to show that the vaccine prevents acute COVID-19 infection. However, Jeffrey Gold, who participated in the study, said in a statement that the new findings “could explain why the incidence of children with Covid-19 is significantly lower than that of adults, as well as a much lower mortality rate. “.
Read also: Minister decides: is the Corona vaccine voluntary or mandatory in Germany?
He said, “Most children receive the first vaccination against measles, mumps and rubella at the age of 12 to 15 months, while they get the second vaccination from the age of four to six.”
Db / ks (Reuters)
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
‘Fast fade’
Initial studies conducted in China, Germany, Britain and other countries have concluded that patients with emerging coronavirus infection develop protective antivirus bodies as part of the body’s immune system, but it appears these bodies only remain effective for a couple of months. . Daniel Altman, professor of immunology at Imperial College London, said that “their effect (protective self-developed bodies) often diminishes rapidly.”
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Two options for vaccine developers
Experts say the rapid weakening of immunity raises serious problems for vaccine developers and public health authorities, as well as for those seeking to distribute these vaccines to protect their people from future epidemics. “For vaccines to be truly effective, there are two options: either the need to develop more robust and longer-term protection … or the vaccine must be obtained regularly,” said Stephen Griffin, assistant professor of medicine at the University of Leeds.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
World race
More than 100 companies and research groups are trying to develop vaccines, of which at least 17 are currently being tested on humans. The American company Moderna announced on Tuesday (July 15, 2020) that clinical trials will enter the final phase on July 27. Moderna is therefore the first company to reach this stage. Russia has announced that it has completed the first clinical trials of an experimental human-tested vaccine, which will be completed by the end of July.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Two doses are “better” than one
In preclinical studies in pigs to monitor the effect of a vaccine developed by the pharmaceutical company (AstraZeneca) for the treatment of Covid-19, known as (AZD 1222), it was found that two doses of the vaccine contributed to the better antibody response of a dose. However, so far, there are no recorded data from any human vaccine trials to show whether any immune response to the antibody will be strong enough or long-lasting.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Time pressure
Geoffrey Arnold, a visiting professor of microbiology at the University of Oxford in Britain and a former expert at Sanofi Pasteur, said the very rapid development and testing of potential vaccines against the Corona virus has been underway for only six months, the which is not enough to show how long vaccines could deliver. Experts predict it will take 12-18 months to produce a safe and effective vaccine from the start of development.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Booster doses
One approach, Griffin-Arnold said, could be that when these vaccines are in development, authorities should consider getting booster doses for millions of people, at regular intervals, or even by combining two or more vaccines for each person. get the best possible protection. However, this can present a major practical challenge. “Giving the whole world one dose of the vaccine is one thing … and giving them multiple doses is another thing entirely,” he said.
.
[ad_2]
Source link
